US FDA delays decision date for Questcor's Acthar for infantile spasms
This article was originally published in Scrip
Executive Summary
The US FDA has postponed the PDUFA date for a supplemental approval of Questcor's HP Acthar gel (repository corticotropin injection) for infantile spasms, due largely to labelling issues.